|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.37 CNY | -0.05% |
|
-3.63% | -26.35% |
| Nov. 12 | Chongqing Zhifei Biological Products Subsidiary Gets China Nod for Shingles, Chickenpox Vaccine | MT |
| Oct. 29 | Zhifei biological products' Q3 net loss at 601.1 million yuan | RE |
| Capitalization | 46.37B 6.57B 5.6B 5.23B 4.92B 9.06B 595B 9.9B 61.05B 23.68B 281B 24.66B 24.14B 1,024B | P/E ratio 2025 * |
-25.6x | P/E ratio 2026 * | 37.5x |
|---|---|---|---|---|---|
| Enterprise value | 41.8B 5.93B 5.05B 4.72B 4.44B 8.17B 537B 8.92B 55.04B 21.35B 253B 22.23B 21.76B 923B | EV / Sales 2025 * |
3.94x | EV / Sales 2026 * | 2.29x |
| Free-Float |
14.76% | Yield 2025 * |
-
| Yield 2026 * | 0.57% |
| 1 day | -0.05% | ||
| 1 week | -3.63% | ||
| Current month | -5.79% | ||
| 1 month | -10.70% | ||
| 3 months | -12.15% | ||
| 6 months | +2.16% | ||
| Current year | -26.35% |
| 1 week | 19.26 |  | 20.23 |
| 1 month | 19.26 | | 21.77 |
| Current year | 18.7 | | 27.8 |
| 1 year | 18.7 | | 28.74 |
| 3 years | 18.7 | | 72.71 |
| 5 years | 18.7 | | 154.13 |
| 10 years | 7.17 | | 154.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhen Jing Li
DFI | Director of Finance/CFO | 43 | 2015-08-18 |
Ren Sheng Jiang
PSD | President | 72 | 2009-08-16 |
Jie Xun
PRN | Corporate Officer/Principal | 36 | 2016-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Ren Sheng Jiang
CHM | Chairman | 72 | 2009-08-16 |
Ling Feng Jiang
BRD | Director/Board Member | 45 | 2018-08-09 |
Zhen Jing Li
BRD | Director/Board Member | 43 | 2018-04-09 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.05% | -3.63% | -32.74% | -66.68% | 6.57B | |
| -0.74% | +3.19% | +1.37% | -0.84% | 76.06B | |
| +2.86% | -0.09% | -33.73% | -38.08% | 58.92B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | |
| -2.24% | -4.93% | +30.25% | +221.80% | 52.48B | |
| +0.93% | -3.97% | +16.04% | -40.22% | 25.54B | |
| +1.85% | -7.39% | +127.81% | +163.37% | 18.76B | |
| -0.72% | -6.94% | +39.18% | +15.08% | 18.73B | |
| -4.52% | -5.15% | +36.59% | +1,036.48% | 15.67B | |
| +1.46% | +2.05% | +173.37% | +704.60% | 14.48B | |
| Average | +0.02% | -2.31% | +42.73% | +206.47% | 34.02B | |
| Weighted average by Cap. | +0.18% | -0.78% | +28.75% | +121.48% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 10.62B 1.51B 1.28B 1.2B 1.13B 2.08B 136B 2.27B 13.99B 5.42B 64.29B 5.65B 5.53B 235B | 16.35B 2.32B 1.97B 1.84B 1.74B 3.2B 210B 3.49B 21.53B 8.35B 98.97B 8.7B 8.51B 361B |
| Net income | -1.81B -257M -219M -204M -192M -354M -23.25B -387M -2.38B -925M -10.96B -963M -943M -39.98B | 762M 108M 92.02M 85.96M 80.88M 149M 9.78B 163M 1B 389M 4.61B 405M 397M 16.83B |
| Net Debt | -4.56B -647M -551M -515M -484M -892M -58.59B -974M -6.01B -2.33B -27.62B -2.43B -2.38B -101B | -8.94B -1.27B -1.08B -1.01B -949M -1.75B -115B -1.91B -11.77B -4.56B -54.09B -4.75B -4.65B -197B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 19.37 ¥ | -0.05% | 12,571,270 |
| 25-12-11 | 19.38 ¥ | -2.22% | 13,976,150 |
| 25-12-10 | 19.82 ¥ | +0.10% | 11,314,790 |
| 25-12-09 | 19.80 ¥ | -1.30% | 12,603,850 |
| 25-12-08 | 20.06 ¥ | -0.20% | 12,785,830 |
End-of-day quote Shenzhen S.E., December 11, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300122 Stock
Select your edition
All financial news and data tailored to specific country editions
